RhyGaze Secures $86 Million Series A Financing to Advance Gene Therapy for Vision Restoration
RhyGaze, a biotechnology company with headquarters in Basel, Switzerland, and Philadelphia, PA, has successfully secured $86 million in Series A financing. The funding will accelerate the development of its groundbreaking gene therapy for optogenetic …